PKC-α regulates cardiac contractility and propensity toward heart failure


The protein kinase C (PKC) family of serine/threonine kinases functions downstream of nearly all membrane-associated signal transduction pathways. Here we identify PKC-α as a fundamental regulator of cardiac contractility and Ca2+ handling in myocytes. Hearts of Prkca-deficient mice are hypercontractile, whereas those of transgenic mice overexpressing Prkca are hypocontractile. Adenoviral gene transfer of dominant-negative or wild-type PKC-α into cardiac myocytes enhances or reduces contractility, respectively. Mechanistically, modulation of PKC-α activity affects dephosphorylation of the sarcoplasmic reticulum Ca2+ ATPase-2 (SERCA-2) pump inhibitory protein phospholamban (PLB), and alters sarcoplasmic reticulum Ca2+ loading and the Ca2+ transient. PKC-α directly phosphorylates protein phosphatase inhibitor-1 (I-1), altering the activity of protein phosphatase-1 (PP-1), which may account for the effects of PKC-α on PLB phosphorylation. Hypercontractility caused by Prkca deletion protects against heart failure induced by pressure overload, and against dilated cardiomyopathy induced by deleting the gene encoding muscle LIM protein (Csrp3). Deletion of Prkca also rescues cardiomyopathy associated with overexpression of PP-1. Thus, PKC-α functions as a nodal integrator of cardiac contractility by sensing intracellular Ca2+ and signal transduction events, which can profoundly affect propensity toward heart failure.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Generation and characterization of Prkca gene–targeted mice.
Figure 2: Transgenic mice expressing PKC-α have reduced ventricular performance.
Figure 3: Changes in PKC-α activity correlate with PLB phosphorylation status and Ca2+ handling.
Figure 4: Loss of Prkca prevents cardiomyopathy in two distinct models of heart failure.
Figure 5: PKC-α regulates PP-1 activity through I-1.
Figure 6: Loss of Prkca rescues cardiomyopathy in mice overexpressing PP-1c.


  1. 1

    Dempsey, E.C. et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Mol. Physiol. 279, L429–L438 (2000).

    CAS  Article  Google Scholar 

  2. 2

    Pass, J.M. et al. Enhanced PKCβII translocation and PKCβII-RACK1 interactions in PKCε-induced heart failure: a role for RACK1. Am. J. Physiol. Heart Circ. Physiol. 281, H2500–H2510 (2001).

    CAS  Article  Google Scholar 

  3. 3

    Ping, P. et al. Ischemic preconditioning induces selective translocation of protein kinase C isoforms ε and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ. Res. 81, 404–414 (1997).

    CAS  Article  Google Scholar 

  4. 4

    MacLennan, D.H. & Kranias, E.G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566–577 (2003).

    CAS  Article  Google Scholar 

  5. 5

    MacDougall, L.K., Jones, L.R. & Cohen, P. Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem. 196, 725–734 (1991).

    CAS  Article  Google Scholar 

  6. 6

    Steenaart, N.A., Ganim, J.R., Di Salvo, J. & Kranias, E.G. The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch. Biochem. Biophys. 293, 17–24 (1992).

    CAS  Article  Google Scholar 

  7. 7

    Neumann, J. Altered phosphatase activity in heart failure, influence on Ca2+ movement. Basic Res. Cardiol. 97, I91–I95 (2002).

    Article  Google Scholar 

  8. 8

    Bayer, A.L. et al. Alterations in protein kinase C isoenzyme expression and autophosphorylation during progression of pressure overload–induced left ventricular hypertrophy. Mol. Cell. Biochem. 242, 145–152 (2003).

    CAS  Article  Google Scholar 

  9. 9

    Bowling, N. et al. Increased protein kinase C activity and expression of calcium-sensitive isoforms in the failing human heart. Circulation 99, 384–391 (1999).

    CAS  Article  Google Scholar 

  10. 10

    Wang, J., Liu, X., Sentex, E., Takeda, N. & Dhalla, N.S. Increased expression of protein kinase C isoforms in heart failure due to myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 284, H2277–H2287 (2003).

    CAS  Article  Google Scholar 

  11. 11

    Carr, A.N. et al. Type 1 phosphatase, a negative regulator of cardiac function. Mol. Cell. Biol. 22, 4124–4135 (2002).

    CAS  Article  Google Scholar 

  12. 12

    El-Armouche, A. et al. Evidence for protein phosphatase inhibitor-1 playing an amplifier role in β-adrenergic signaling in cardiac myocytes. FASEB J. 17, 437–439 (2003).

    CAS  Article  Google Scholar 

  13. 13

    Arber, S. et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88, 393–403 (1997).

    CAS  Article  Google Scholar 

  14. 14

    Bibb, J.A. et al. Phosphorylation of the protein phosphatase inhibitor-1 by Cdk5. J. Biol. Chem. 276, 14490–14497 (2001).

    CAS  Article  Google Scholar 

  15. 15

    Hubbard, M.J., Dent, P., Smythe, C. & Cohen, P. Targeting of protein phosphatase 1 to the sarcoplasmic reticulum of rabbit skeletal muscle by a protein that is very similar or identical to the G subunit that directs the enzyme to glycogen. Eur. J. Biochem. 189, 243–249 (1990).

    CAS  Article  Google Scholar 

  16. 16

    Champion, H.C. et al. Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to the study of phospholamban physiology. Circulation 108, 2790–2797 (2003).

    CAS  Article  Google Scholar 

  17. 17

    Klein, L. et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am. J. Cardiol. 91, 18F–40F (2003).

    CAS  Article  Google Scholar 

  18. 18

    Minamisawa, S. et al. Chronic phospholamban–sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313–322 (1999).

    CAS  Article  Google Scholar 

  19. 19

    Hoshijima, M. et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864–871 (2002).

    CAS  Article  Google Scholar 

  20. 20

    Warner-Stevenson, L. Clinical use of inotropic therapy for heart failure: looking backward or forward? Circulation 108, 492–497 (2003).

    Article  Google Scholar 

  21. 21

    Bristow, M.R. β-Adrenergic receptor blockade in chronic heart failure. Circulation 101, 558–569 (2000).

    CAS  Article  Google Scholar 

  22. 22

    Hahn, H.S. et al. Protein kinase Cα negatively regulates systolic and diastolic function in pathological hypertrophy. Circ. Res. 93, 1111–1119 (2003).

    CAS  Article  Google Scholar 

  23. 23

    Arber, S. et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 7, 393–403 (1997).

    Article  Google Scholar 

  24. 24

    Liang, Q. et al. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 22, 5079–5089 (2003).

    CAS  Article  Google Scholar 

  25. 25

    Bueno, O.F. et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341–6350 (2000).

    CAS  Article  Google Scholar 

  26. 26

    Westfall, M.V. & Borton, A.R. Role of troponin I phosphorylation in protein kinase C–mediated enhanced contractile performance of rat myocytes. J. Biol. Chem. 278, 33694–33700 (2003).

    CAS  Article  Google Scholar 

  27. 27

    Petrashevskaya, N.N., Bodi, I., Rubio, M., Molkentin, J.D. & Schwartz, A. Cardiac function and electrical remodeling of the calcineurin-overexpressed transgenic mouse. Cardiovasc. Res. 54, 117–132 (2002).

    CAS  Article  Google Scholar 

  28. 28

    Masaki, H., Sato, Y., Luo, W., Kranias, E.G. & Yatani, A. Phospholamban deficiency alters inactivation kinetics of L-type Ca2+ channels in mouse ventricular myocytes. Am. J. Physiol. 272, H606–H612 (1997).

    CAS  Google Scholar 

  29. 29

    Chu, G. et al. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. 79, 1064–1076 (1996).

    CAS  Article  Google Scholar 

  30. 30

    De Windt, L.J., Lim, H.W., Haq, S., Force, T. & Molkentin, J.D. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J. Biol. Chem. 275, 13571–13579 (2000).

    CAS  Article  Google Scholar 

  31. 31

    Braz, J.C., Bueno, O.F., De Windt, L.J. & Molkentin, J.D. PKCα regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase 1/2 (ERK1/2). J. Cell. Biol. 156, 905–919 (2002).

    CAS  Article  Google Scholar 

Download references


This work was supported by the National Institutes of Health, an Established Investigator Award from the American Heart Association, and a Pew Charitable Trust Scholar Award (J.D.M.). J.C.B. was supported by a National Institutes of Health training grant (5T32 HL07382). J.A.B. was supported by the National Institute of Drug Abuse. We thank T. Eschenhagen for the I-1-expressing adenovirus and S. Schenolikar for antibodies to I-1 and Thr35-phoshorylated I-1.

Author information



Corresponding author

Correspondence to Jeffery D Molkentin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Braz, J., Gregory, K., Pathak, A. et al. PKC-α regulates cardiac contractility and propensity toward heart failure. Nat Med 10, 248–254 (2004).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing